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Towards Organometallic Antischistosomal Drug Candidates 1	
 2	
Key Terms 3	
Organometallic complexes: Organometallic complexes are metal-based 4	
compounds, which have at least a direct bond between a metal centre and a 5	
carbon atom.[1] The most representative examples of this class of 6	
compounds are metallocenes, metal-arenes or metal-carbonyl complexes.[1] 7	
Ferrocene: Ferrocene is an organometallic compound, which is characterized 8	
by two cyclopentadienyl rings sandwiching a Fe(II) atom. It is the most studied 9	
organometallic compound to date.[1]  10	
Ferroquine: Ferroquine is a ferrocenyl derivative of the organic antimalarial 11	
drug chloroquine. In contrast to the parent organic drug, Ferroquine is also 12	
active on P. falciparum strains which are resistant to chloroquine.[2] 13	
Ferroquine is the most advanced organometallic-containing drug candidate. 14	
 15	
 16	
  17	
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Abstract 18	
In the recent years, there has been an increasing interest in the use of novel 19	
approaches for the treatment of parasitic diseases such as schistosomiasis. 20	
Among the different approaches used, organometallic compounds were found 21	
to offer unique opportunities in the design of antiparasitic drug candidates. A 22	
ferrocenyl derivative, namely ferroquine, has even entered clinical trials as a 23	
novel antimalarial. In this short review, we report on the studies describing the 24	
use of organometallic compounds against schistosomiasis. 25	
 26	
Background 27	
In the developing world, particularly in tropical and subtropical regions of sub-28	
Saharan Africa, Asia and America, parasitic helminth infections are a major 29	
human health problem affecting more than 1.5 billion people.[3] Of these 30	
infections, schistosomiasis, a neglected tropical disease (NTD) also named 31	
bilharzia, is one of the most prevailing parasitic diseases. It is caused by a 32	
genus of trematodes, schistosomes, which are dioecious blood flukes with a 33	
complex life cycle.[3] Schistosoma haematobium, S. mansoni, S. intercalatum, 34	
S. japonicum and S. mekongi are the five species responsible for human 35	
infections leading either to intestinal or urogenital schistosomiasis.[4] Each 36	
year, 11,700 deaths are reported, though the real figure might be as high as 37	
280,000, which are related to the severe consequences of the infection such 38	
as fibrosis, renal failure or bladder cancer.[5-7] Even more worrying are the 39	
number of people infected worldwide (more than 207 million) and the number 40	
of people at risk of being infected (almost 800 million people), and this is 41	
among the world`s poorest populations.[8] In contrast to classical “first world 42	
diseases” and the so called big three diseases (malaria, tuberculosis and 43	
HIV/Aids), NTDs have attracted much lower research interests. This fact is 44	
easily reflected in the lack of new chemical entities (NCE) introduced into the 45	
market between 1999 and 2011 for NTDs.[9] Not only the number of available 46	
and approved drugs for NTDs is limited but also their development is lacking. 47	
This can be seen in the number of registered clinical trials in the period 1999-48	
2011 focusing on NTDs: only 2016 out of 148 000 registrations are linked to 49	
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NTDs (about 1%).[10, 11] As a matter of fact, since the market launch of 50	
praziquantel (PZQ), which is the only available drug since the 1970s to treat 51	
all classes of schistosomiasis, no new drug has entered the market.[12]  52	
Please note that the chemotherapeutic treatment of schistosomiasis gradually 53	
increased from 12.4 million people in 2006 to over 42.1 million people treated 54	
in 2012 and is expected to increase further.[13, 14] 55	
The past decade has seen the rapid development of organometallic 56	
compounds, which are metal complexes containing at least one direct metal-57	
carbon bond, in various fields such as medicinal chemistry and chemical 58	
biology.[1, 15-22] Traditionally, organometallic compounds are noted to be 59	
relatively lipophilic, regularly uncharged and the metal centre is in a low 60	
oxidation state, making them attractive for biological purposes.[1] Indeed, 61	
organometallic compounds notably ferrocenyl derivatives[23, 24] have shown 62	
over the recent years promising anticancer[25], antibacterial[26] and 63	
antimalarial[27] properties. The advantages of organometallic derivatization of 64	
known organic drugs such as the antimalarial drug chloroquine (ferroquine) or 65	
the anticancer agent tamoxifen (ferrocifen) have been exemplified in the 66	
pioneering work of Biot,[27] Jaouen and co-workers.[28] In both examples, the 67	
incorporation of a ferrocenyl moiety into the organic drug allowed new and 68	
unique metal-specific modes of action to be unveiled in addition to superior 69	
activities compared to the parent drugs.  70	
In this short review article, we highlight, on the basis of selected literature 71	
examples, the recent achievements on the design of organometallic drug 72	
candidates as antischistosomal agents. We especially focus our attention on 73	
the advantages provided by the addition of an organometallic moiety into a 74	
drug candidate. Of note, we are describing only the reports on organometallic 75	
compounds. Those related to classical coordination metal complexes are 76	
intentionally omitted. The organometallic compounds presented in this short 77	
review are categorized into three main groups according to the nature of the 78	
parent organic drug and their metal derivatization (antifungal agents as 79	
antischistosomal drug candidates, antimalarial agents as antischistosomal 80	
drug candidates and organometallic derivatives of PZQ). Their in vitro and/or 81	
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in vivo antischistosomal activity, cytotoxicity and stability, when possible, are 82	
discussed in detail.  83	
 84	
Antifungal agents as antischistosomal drug candidates 85	
Over the recent years, metal-drug synergism was shown to hold great 86	
promise for the development of antiparasitic drug candidates.[29, 30] This 87	
approach makes use of the combination of a biologically active drug and a 88	
metal fragment to further enhance the biological activity of the parent 89	
molecule.[29] For example, the application of such a strategy was previously 90	
investigated by the group of Sanchez-Delgado, who prepared 91	
organoruthenium complexes bearing the azoles antifungal agents clotrimazole 92	
and ketoconazole as coordinating ligands and investigated their antiparasitic 93	
effect against Leishmania major (causing leishmaniasis) and Trypanosoma 94	
cruzi (the causative agent of Chagas disease).[29, 31] Complexation of 95	
clotrimazole to a ruthenium complex increased the activity of the organic drug 96	
against L. major and T. cruzi by a factor of 110 and 58, respectively, while no 97	
toxicity to human osteoblast was observed. 98	
In the field of antischistosomal drug candidates, a series of miconazole (mcz) 99	
organoruthenium complexes with the general formula [(η6-p-100	
cymene)RuCl2(mcz)], [(η6-p-cymene)RuCl(mcz)2]Cl and [(η6-p-101	
cymene)Ru(mcz)3](PF6)2 were synthesized by Turel et al. as potential 102	
antifungal and antischistosomal agents (Figure 1).[32]  103	
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	104	
Figure 1. Structures of the antifungal miconazole (mcz), the dimeric ruthenium 105	
precursor (P1) and the general formulas of the mono-, bis-, and tris-azole 106	
organoruthenium species. The azole ligands are abbreviated and linked via the N3 107	
imidazole nitrogen atom of miconazole. Figure adapted from ref.[32] 108	
 109	
In their study, the authors used the dimeric ruthenium precursor [(η6-p-110	
cymene)RuCl]2(μ-Cl)2 (P1) as a reference compound and compared its 111	
activity to the respective mono-, bis- and tris-azole organoruthenium species 112	
prepared. No effect was observed when P1 was incubated with adult S. 113	
mansoni for 72 h at a concentration of 100 μg/mL. In contrast, the mcz 114	
complexes ([(η6-p-cymene)RuCl2(mcz)], [(η6-p-cymene)RuCl(mcz)2]Cl and 115	
[(η6-p-cymene)Ru(mcz)3](PF6)2) had an increasing activity at 100 μg/mL after 116	
24–48 h post-incubation with decreasing numbers of mcz ligands ([(η6-p-117	
cymene)RuCl2(mcz)] > [(η6-p-cymene)RuCl(mcz)2]Cl > [(η6-p-118	
cymene)Ru(mcz)3](PF6)2). Interestingly, [(η6-p-cymene)Ru(mcz)3](PF6)2 119	
showed a sex-specific in vitro activity. After 72 h incubation of [(η6-p-120	
cymene)Ru(mcz)3](PF6)2, all male worms died, while female worms showed 121	
decreased mortality.[32] Of note, a slow decomposition of the monoazole 122	
complex in DMSO, which was the solvent used in the bioassay, was observed. 123	
Such behaviour was also observed with other similar antiparasitical and 124	
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anticancer organometallic candidates.[33] Therefore, the in vitro results 125	
obtained for compound [(η6-p-cymene)RuCl2(mcz)] are a combination of the 126	
activity of mcz, compound [(η6-p-cymene)RuCl2(mcz)] and of [(η6-p-127	
cymene)RuCl2(DMSO)]. However, as nicely described by the authors, no 128	
decomposition of the di- and tri-substituted complexes was observed in 129	
DMSO. 130	
 131	
Antimalarial agents as antischistosomal drug candidates 132	
Drug-repurposing has become an important tool over the past years for the 133	
discovery and development of new medicines. This strategy, particularly for 134	
neglected diseases where research is mostly academically driven, can allow 135	
saving an enormous amount of time, money and effort.[34] Technically 136	
speaking, the aim is to use an already known and/or approved drug to treat a 137	
(completely) different disease.[35] In the case of schistosomiasis, whose 138	
treatment relies on a single drug (PZQ), new perspectives are urgently 139	
needed to supply the drug development pipeline with new lead compounds. 140	
Therefore, this strategy might hold great promise.[35] Besides the economical 141	
perspective, another advantage might be the ability to treat two diseases 142	
simultaneously. For example, since helminth infections and malaria are often 143	
coendemic, treatment with an antimalarial drug in patients suffering from a 144	
Plasmodium/schistosome co-infection might show an ancillary effect on 145	
schistosomiasis.[36] Since both blood-feeding parasites, Plasmodium and 146	
Schistosoma, share the heme degradation pathway, drug candidates might 147	
interact with similar targets.[37] With this in mind, our groups in collaboration 148	
with the one of Biot used this approach and analysed the potential of the 149	
organometallic antimalarial drug candidates ferroquine, ruthenoquine and 150	
hydroxyl-ferroquine (Figure 2) as antischistosomal agents.[38-40] For 151	
comparison, the known antimalarial drugs chloroquine and mefloquine were 152	
used as reference compounds. Of note, the latter is known for its 153	
antischistosomal effects.[41] Ruthenoquine and hydroxyl-ferroquine were 154	
employed in this study to assess if redox-activity and/or production of reactive 155	
oxygen species (ROS) could be playing a role in the potential biological 156	
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activity. Indeed, contrary to ferroquine, ruthenoquine cannot be oxidized under 157	
physiological conditions while hydroxyl-ferroquine can produce hydroxyl 158	
radicals like ferroquine but has reduced cytotoxic effects.[42] 159	
	160	
Figure 2. Chemical structures of chloroquine, mefloquine, ferroquine, hydroxyl-161	
ferroquine and ruthenoquine. Figure adapted from ref.[38] 162	
 163	
The cytotoxicity of all compounds was first evaluated on both cervical cancer 164	
cells (HeLa) and non-cancerous cells (MRC-5) to ensure that the compounds 165	
were selective towards parasites over cells. Mefloquine was shown to be the 166	
most toxic, while the other organometallic compounds showed moderate 167	
toxicity. Among the organometallic derivatives, ruthenoquine displayed the 168	
lowest toxicity (IC50 values of 21.9 μM and 8.8 μM on MRC-5 and HeLa cell 169	
lines, respectively), while both ferrocenyl derivatives (ferroquine and hydroxyl-170	
ferroquine) indicated cytotoxicities in a similar range[43]. The antischistosomal 171	
activity of the compounds was then assessed on newly transformed 172	
schistosomula (NTS) and adult S. mansoni both in vitro and in vivo. The in 173	
vitro results of all organometallic derivatives revealed a moderate 174	
antischistosomal activity against both NTS and adult S. mansoni. Within all 175	
organometallic compounds tested, ruthenoquine, which does not produce 176	
reactive oxygen species, was found to be the most effective. 72 h post-177	
incubation with 33 μM of ruthenoquine, all NTS were dead whereas NTS 178	
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treated with ferroquine and hydroxyl-ferroquine showed reduced viability. The 179	
same trend was observed on adult S. mansoni. Exposure to ruthenoquine led 180	
to the strongest reduction in viability, and several dead worms were observed 181	
72 h after post-incubation. In vivo studies revealed only weak 182	
antischistosomal activity of the organometallic compounds with the highest 183	
total worm burden reduction for ferroquine (19.4% and 35.6% when treated 184	
with 200 and 800 mg/kg, respectively). An even lower total worm burden 185	
reduction of 17.3% at 200 mg/kg was observed for hydroxyl-ferroquine, while 186	
ruthenoquine indicated no activity at this dosage. These observations show 187	
that in vitro results cannot always be translated into in vivo results. Of note, no 188	
antischistosomal activity was observed for chloroquine both in vitro and in 189	
vivo.[38]	 The results obtained suggest that ferrocenyl and ruthenocenyl 190	
derivatization of the antimalarial drug chloroquine is not significantly improving 191	
its antischistosomal activity. 192	
 193	
Organometallic derivatives of praziquantel 194	
As mentioned above, PZQ is the only available drug available against 195	
schistosomiasis.[8, 44] Apart from its broad-spectrum of activity, there are two 196	
main drawbacks associated with the use of PZQ, namely its inactivity against 197	
juvenile Schistosoma and its rather low metabolic stability in vivo.[45-47] 198	
Indeed, hydroxylation at the cyclohexane ring leads to the major metabolite 199	
(PZQ-OH), which lacks the activity of the parent drug (Figure 3). 200	
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	201	
Figure 3. General structures of praziquantel (PZQ), the major metabolite (PZQ-OH) 202	
and the three classes of different organometallic derivatizaton (Type -A, -B and –C). 203	
Figure adapted from ref.[48] 204	
	205	
With millions of people treated for schistosomiasis with a single drug, not very 206	
surprisingly, a reduced susceptibility of schistosomes to PZQ was recently 207	
reported in the literature.[49-51] This encouraged us to actively engage in this 208	
research field and hence two years ago we started a program on 209	
organometallic modifications of PZQ. Initially, 18 ferrocenyl derivatives of PZQ 210	
were synthesized, which are divided into two structural classes (Type A & 211	
Type B).[52] Type-A class of compounds lacks the cyclohexane ring of PZQ, 212	
which might avoid the transformation to a hydroxylated metabolite with 213	
reduced activity. Instead, the ferrocenyl moiety is attached to the 214	
praziquanamine by various linkers. The second class of compounds (Type-B) 215	
bears a piperidine instead of a cyclohexane ring where the ferrocenyl moiety 216	
is attached. Previous studies on the parent drug suggest that such 217	
modifications should not reduce the anthelmintic activity.[53, 54]  218	
More specifically, we could demonstrate a high stability of the compounds in 219	
human plasma using a LC-MS technique.[55] This observation contradicts the 220	
common thinking that some organometallic compounds could be unstable in a 221	
biological environment. The cytotoxicity against two mammalian cell lines 222	
(HeLa and MRC-5) was then evaluated to ensure the selectivity of the 223	
compounds. The resulting 18 organometallic derivatives achieved only 224	
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moderate cytotoxicities toward HeLa cell (IC50 values in a range of 16.9 – 97.7 225	
M) and did not strongly affect healthy MRC-5 cell. Interestingly, most of the 226	
ferrocenyl derivatives, with the exception of one diferrocenyl type-B 227	
compound (X = CO, n = 2), showed a strong decrease in their cytotoxicity on 228	
a noncancerous cell line (MRC-5) compared to HeLa cells.  229	
Finally, the in vitro antischistosomal activity against adult S. mansoni was 230	
evaluated. Out of the 18 ferrocenyl derivatives, only 4 compounds, which all 231	
belong to the type-A class, showed antischistosomal activity at 30 g/mL in 232	
vitro. Since only a moderate antischistosomal activity was observed for these 233	
eighteen ferrocenyl derivatives of PZQ, a different organometallic modification 234	
was envisaged. Hence, the aromatic part of PZQ was complexed with a 235	
Cr(CO)3 core (Type C). It was hypothesized that this organometallic fragment 236	
might decrease the metabolic instability of PZQ and improve the general 237	
physicochemical properties of the parent drug by increasing for example its 238	
lipophilicity.[48] The evaluated lipophilicities, given as the logarithmic 239	
distribution coefficient (D) at physiological conditions (pH =7.4), of both 240	
compounds 1 (LogD7.4 = 3.49) and 2 (LogD7.4 = 3.59) were significantly higher 241	
than that of PZQ (LogD7.4 = 2.66) and were attributed to the presence of the 242	
Cr(CO)3 moiety. The membrane permeability or 1 and 2 was therefore 243	
assumed to be increased compared to PZQ. The in vitro studies of the Cr-244	
PZQ derivatives against adult S. mansoni revealed an impressive 245	
submicromolar antischistosomal activity of 1 (0.25 M) and 2 (0.27 M), with 246	
a biological effect in a comparable range than the parent drug PZQ (0.1 M). 247	
Importantly, 1 and 2 were found to be mainly non toxic on the cervical cancer 248	
(HeLa) and non-cancerous (MRC-5) cell lines, showing therefore a promising 249	
selectivity for parasites.[48]  250	
The stability of both Cr-PZQ derivatives were preliminary investigated by 1H 251	
Nuclear Magnetic Resonance (NMR) spectroscopy to ensure that the 252	
anthelmintic activity is not due to a release of the organometallic Cr(CO)3 core. 253	
The compounds were found to be stable up to two days in a [D6]DMSO/D2O 254	
mixture. These findings were further supported with human plasma stability 255	
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experiments, which showed no significant decomposition after incubation for 256	
24 hours at 37 °C.  257	
Further bioassays were undertaken to study in-depth the in vitro metabolic 258	
behaviour of both chromium compounds using human liver microsomes.[56] 259	
In general, the metabolic profile obtained for 1 and 2 shows crucial differences. 260	
While 1 is mainly demetallated to PZQ or hydroxylated to cis-4-PZQ-OH, 2 261	
shows only minor demetallation and hydroxylation. The major metabolite of 2 262	
could be identified as [(η6-praziquanamine)Cr(CO)3], formed after cleavage of 263	
the cyclohexanoyl moiety. The detailed metabolic profiles of 1 and 2 are 264	
shown in Figure 4.[56] 265	
	266	
Figure 4. Metabolic profile of 1 and 2 suggested by Gasser and co-workers. For 267	
compounds 1 and 2, see Figure 3. Figure taken from ref.[56] 268	
 269	
At this stage, it is necessary to clarify that only one of the enantiomers of the 270	
parent drug PZQ ((R)-PZQ) exhibits an antischistosomal activity in vitro. Also, 271	
(R)-PZQ is believed to have fewer adverse events than the (S)-PZQ 272	
enantiomer.[57] Consequently, optically pure (η6-PZQ)Cr(CO)3 derivatives, 273	
namely (R,RP)-1, (S,SP)-1, (S,RP)-2 and (R,SP)-2 were synthesized and 274	
investigated for their in vitro antischistosomal activity against adult S. mansoni 275	
(Figure 5).  276	
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	277	
Figure 5. Synthesis of optically pure (η6-PZQ)Cr(CO)3 derivatives starting from S-PZQ 278	
and R-PZQ. Figure taken from ref.[56] 279	
 280	
A clear difference in activity was observed, with the lowest IC50 value for 281	
(R,RP)-1 of 0.08 M, followed by (R,SP)-2 with 0.13 M. The (S)-enantiomers 282	
((S,SP)-1, (S,RP)-2) exhibited IC50 values higher than 66.9 M and are 283	
therefore considered as inactive (see Table 1).  284	
Table 1. In vitro antischistosomal activity against adult S. mansoni of enantiomeric 285	
mixtures of compounds 1 and 2, PZQ and optically pure derivatives. Table taken from 286	
ref.[56] 287	
Compound IC50 (M) Compound IC50 (M) 
PZQ 0.10   
1a 0.25 (R,RP)-1 0.08 
  (S,SP)-1 >66.9 
2a 0.27 (R,SP)-2 0.13 
  (S,RP)-2 >66.9 
a Racemic mixture. 288	
These observations tend to suggest that the (R)-enantiomers of (η6-289	
PZQ)Cr(CO)3 have the same target as PZQ. Rac-1 and Rac-2 were then 290	
given to mice harbouring adult S. mansoni to evaluate their in vivo 291	
antischistosomal activity. Relatively low total worm burden reduction of 24% 292	
and 29%, respectively were obtained with single doses of 400 mg/kg of 1 and 293	
N
O
(R)
N
O
CrOC
OC CO
H
N
O
(S)
N
O
CrOC
OC CO
H
(S, Sp)-1
S-PZQ
N
O
(S)
N
O
CrOC
OC CO
H
(S, Rp)-2 (R, Sp)-2
(R, Rp)-1
N
O
(R)
N
CrOC
OC CO
H
Enantiomers
Enantiomers
DiastereomersDiastereomers Diastereomers
R-PZQ
Cr(CO)6 Cr(CO)6
140°C 140°C
N
O
(S)
N
O
H
N
O
(R)
N
O
H
13 
	
2. Of note, with the same dosage of 400 mg/kg, PZQ reached a total worm 294	
burden reduction of 96%.[58] Distribution problems or protein binding might 295	
explain these relatively disappointing in vivo results[56]. Of note, death of 296	
mice was observed during this in vivo study. Contrary to expectations, it is 297	
very important to mention that a release of the Cr(CO)3 core cannot be 298	
responsible for the observed toxicities. Assuming that all chromium given to 299	
mice was transformed into Cr(III) (note that this transformation involves the 300	
passage through other oxidation states), the amount of Cr(III) would not be 301	
sufficient to kill mice since Cr(III) salts have LD50 values in the range 3.2 – 15 302	
g/kg when given orally to mice.[56, 59] Taken together, the toxicity observed 303	
in mice during the in vivo studies may be rationalized with the parasitic 304	
infection itself and is most likely not related with the administration of the 305	
chromium compounds. 306	
 307	
 308	
Future perspectives 309	
There is undoubtedly a need for novel antischistosomal drug candidates. To 310	
tackle this global problem, it is extremely important that different perspectives 311	
are employed to enlarge as soon as possible the pool of compounds to be 312	
tested. Therefore, the use of organometallic compounds as antischistosomal 313	
agents is definitively not an idea to be put aside. Considering the extremely 314	
low amount of literature on this topic (to the best of our knowledge, there are 315	
only 5 publications reported on this subject to date) and the relatively 316	
promising results obtained, we strongly believe that much more efforts should 317	
be put into this research area. Organometallic compounds clearly offer new 318	
and unique opportunities. In addition, potentially, novel metal-mediated modes 319	
of action could be unveiled. We are currently assessing the activity of novel 320	
organometallic derivatives and our results will be published in due course. 321	
 322	
Executive summary 323	
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Background 324	
 Schistosomiasis is a parasitic helminth infection, which belongs to the 325	
neglected tropical disease (NTD). 326	
 More than 200 million people are infected with schistosomes and over 327	
800 million people are at risk. 328	
 Current treatment options rely on praziquantel. 329	
 This review discusses the potential of the synthetic modification of 330	
known antischistosomal agents with organometallic compounds to 331	
provide new lead compounds against schistosomiasis. 332	
 333	
 334	
Antifungal agents as antischistosomal drug candidates 335	
 Metal-drug synergism is exemplified with the biological evaluation of a 336	
series of miconazole (mcz) organoruthenium complexes as 337	
antischistosomal agents. 338	
 The in vitro antischistosomal results for three different complexes, 339	
namely [(η6-p-cymene)RuCl2(mcz)], [(η6-p-cymene)RuCl(mcz)2]Cl and 340	
[(η6-p-cymene)Ru(mcz)3](PF6)2, are discussed and compared to a 341	
dimeric ruthenium precursor. 342	
 A sex-specific in vitro activity for [(η6-p-cymene)Ru(mcz)3](PF6)2 was 343	
observed. 344	
 345	
Antimalarial agents as antischistosomal drug candidates 346	
 Drug-repurposing has become an interesting tool for the cost-effective 347	
development of new drugs. Not surprisingly, researchers have tried to 348	
find new lead compounds as antischistosomal drugs using this 349	
technique.  350	
15 
	
 The in vitro and in vivo antischistosomal effect of organometallic 351	
antimalarial drug candidates such as ferroquine, ruthenoquine and 352	
hydroxyl-ferroquine is discussed in depth in this section. 353	
 354	
Organometallic derivatives of praziquantel 355	
 The widespread possibilities of organometallic derivatization of a 356	
known organic antischistosomal drug such as praziquantel is described 357	
in this part of the review.  358	
 The in vitro antischistosomal activity of eighteen ferrocenly derivatives 359	
of PZQ, which belong to two different structural classes, is discussed. 360	
 In vitro and in vivo studies on two organometallic modified PZQ at the 361	
aromatic part with a Cr(CO)3 core are presented.  362	
 The in vitro metabolic behaviour of two chromium compounds is 363	
highlighted.  364	
 365	
* [52]: Patra M, Ingram K, Pierroz V et al.: Ferrocenyl Derivatives of the 366	
Anthelmintic Praziquantel: Design, Synthesis, and Biological Evaluation. J. 367	
Med. Chem 55(20), 8790-8798 (2012). 368	
 - This article present the first ferrocenyl modified praziquantel 369	
derivatives as well as their in vitro antischistosomal activity. 370	
 371	
* [48]: Patra M, Ingram K, Pierroz V et al.: [(η6-Praziquantel)Cr(CO)3] 372	
Derivatives with Remarkable In Vitro Anti-schistosomal Activity. Chem. Eur. J. 373	
19(7), 2232-2235 (2013). 374	
- This article shows the impressive in vitro antischistosomal activity of 375	
two chromium compounds. 376	
 377	
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* [56]: Patra M, Ingram K, Leonidova A et al.: In Vitro Metabolic Profile and in 378	
Vivo Antischistosomal Activity Studies of (n6-Praziquantel)Cr(CO)3 379	
Derivatives. J. Med. Chem 56(22), 9192-9198 (2013). 380	
 381	
‐ This article presents an in-depth biological study of Cr(CO)3(PZQ). 382	
 383	
* [38]: Keiser J, Vargas M, Rubbiani R, Gasser G, Biot C: In vitro and in vivo 384	
antischistosomal activity of ferroquine derivatives. Parasites & Vectors 7(1), 385	
424 (2014). 386	
 - This article presents an exemplified drug-repurposing study of known 387	
organometallic antimalarial drug candidates as antischistosomal agents. 388	
 389	
* [32]: Kljun J, Scott AJ, Lanisnik Rizner T, Keiser J, Turel I: Synthesis and 390	
Biological Evaluation of Organoruthenium Complexes with Azole 391	
Antifungal Agents. First Crystal Structure of a Tioconazole Metal 392	
Complex. Organometallics 33(7), 1594-1601 (2014). 393	
 394	
‐ This article show drug-synergism adapted for an antifungal 395	
organoruthenium complex and translated it for antischistosomal 396	
purposes. 397	
 398	
* [2]: Biot C, Glorian G, Maciejewski LA, Brocard J: Synthesis and antimalarial 399	
activity in vitro and in vivo of a new ferrocene−chloroquine analogue. J. Med. 400	
Chem. 40, 3715-3718 (1997). 401	
- This is the seminal article on Ferroquine, the ferrocenyl analogue of 402	
chloroquine, which went into phase II clinical trial. 403	
 404	
* [28]: Hillard EA, Vessieres A, Jaouen G: Ferrocene Functionalized 405	
Endocrine Modulators as Anticancer Agents. In: Medicinal Organometallic 406	
Chemistry (Topics in Organometallic Chemistry), Jaouen G, Metzler-Nolte N 407	
(Ed.^(Eds). Springer, Heidelberg, Germany 81-117 (2010). 408	
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- This book chapter presents the recent advences on Ferroquine, the 409	
ferrocenyl analogue of the anticancer drug Tamoxifen. 410	
 411	
*[11]: Njoroge M, Njuguna NM, Mutai P, Ongarora DSB, Smith PW, Chibale K: 412	
Recent Approaches to Chemical Discovery and Development Against Malaria 413	
and the Neglected Tropical Diseases Human African Trypanosomiasis and 414	
Schistosomiasis. Chem. Rev. 114(22), 11138-11163 (2014). 415	
 - This review highlights the recent approches to chemical discovery for 416	
neglected tropical diseases such as schistosomiasis.  417	
 418	
	419	
 420	
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